Rheumatoid arthritis ICD-10 M05 · ICD-11 FA20

Rheumatoid Arthritis When Methotrexate Is Contraindicated and the First Alternative csDMARD Strategy Has Not Worked

This protocol covers a specific and common challenge: the patient with rheumatoid arthritis who cannot use methotrexate, who has no poor prognostic features, and whose initial conventional synthetic DMARD alternative has fallen short of the treatment target.

Clinical Scenario

The patient has a contraindication or early intolerance to methotrexate and is without poor prognostic factors — meaning no high-level RF or ACPA positivity, no persistently moderate or high disease activity despite prior csDMARD therapy, no high swollen joint count, no markedly elevated acute phase reactants, no early erosions, and no history of failure of two or more csDMARDs.

Previous Treatment — Target Not Reached

An initial strategy of leflunomide or sulfasalazine combined with short-term glucocorticoids was used as the first-line approach (given the methotrexate contraindication). That strategy did not achieve the required benchmarks: at least 50% improvement in disease activity within 3 months, or sustained remission or low disease activity by 6 months. This protocol defines the next step.

Next-Line Approach — Partial Overview

When the initial csDMARD strategy has not reached the treatment target, the next step involves adding a biologic DMARD (bDMARD) combined with a csDMARD. Depending on individual patient risk factors — including cardiovascular, malignancy, and thromboembolic considerations — a targeted synthetic DMARD may also be evaluated. The complete agent selection guidance, sequencing, and monitoring plan are in the full protocol.

Treatment Targets

At least 50% improvement in disease activity within 3 months
Sustained remission or low disease activity by 6 months

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2022-223356

In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine should be considered as part of the (first) treatment strategy.
If the treatment target is not achieved with the first csDMARD strategy, in the absence of poor prognostic factors, other csDMARDs should be considered.
If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present, a bDMARD should be added; JAK-inhibitors may be considered, but pertinent risk factors must be taken into account.
bDMARDs and tsDMARDs should be combined with a csDMARD; in patients who cannot use csDMARDs as comedication, IL-6 pathway inhibitors and tsDMARDs may have some advantages compared with other bDMARDs.
Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.

View source ↗